<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03723486</url>
  </required_header>
  <id_info>
    <org_study_id>15-8784-AE</org_study_id>
    <secondary_id>TB2-138775</secondary_id>
    <nct_id>NCT03723486</nct_id>
  </id_info>
  <brief_title>Bariatric Surgery: Microbiome &amp; Diabetes</brief_title>
  <official_title>Changes in the Intestinal and Oral Microbiome of Morbidly Obese Patients Undergoing Gastric Bypass Surgery in Relation to Insulin Resistance and Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective cohort study, following 80 morbidly obese patients undergoing&#xD;
      bariatric surgery, specifically Roux-en-Y gastric bypass (RYGB). The investigators are&#xD;
      measuring intestinal microbiota (IM) and oral microbiota (OM) at the beginning before any&#xD;
      treatment, at the time of surgery, which is after a very low calorie standard diet, and 1 and&#xD;
      6 months after surgery. The investigators assess whether changes in IM are related to changes&#xD;
      in insulin resistance (IR), other features of the metabolic syndrome (MetS) and OM.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Morbid obesity is associated with not only type 2 diabetes (T2D) of morbidly obese patients),&#xD;
      but also cardiovascular complications, all of which remarkably improved and even resolved&#xD;
      with bariatric surgery, of which the RYGB surgery has become the gold standard. Many studies&#xD;
      have shown that within a few weeks post-RYGB there is dramatic improvement in IR and/or T2D&#xD;
      independent of weight loss that ensues. These results led us to hypothesize that changes in&#xD;
      intestinal microbiome (IM) composition and metagenome may be independently associated with&#xD;
      improvement in metabolic parameters in humans undergoing RYGB.&#xD;
&#xD;
      Another aspect of RYGB that has not been studied is the potential changes in oral microbiome&#xD;
      (OM) and salivary proteome (SP) and their relationship with weight loss and metabolic&#xD;
      improvement. Understanding the OM and SP in morbidly obese patients before and after RYGB is&#xD;
      important because shifts in the OM and SP may explain the susceptibility of these patients&#xD;
      for oral infections like periodontal disease, which is more prevalent and severe in this&#xD;
      population, particularly if T2D is present To our knowledge there are no longitudinal studies&#xD;
      the relation between oral and intestinal microbiome before and after bariatric surgery.&#xD;
      Furthermore, there are no studies looking at the effect of weight-reduction with the very low&#xD;
      calorie diet (VLCD) Optifast regimen on IM, which the investigators plan to do. As IM may&#xD;
      contribute to obesity and IR/T2D, the latter being the most dominant feature of the MetS.&#xD;
      However, whether specific IM compositions are associated with improvement of obesity, IR/T2D&#xD;
      and other features of the MetS is not clear; and the effects of RYGB on IM for treatment of&#xD;
      these disorders in morbid obesity have not been well studied.&#xD;
&#xD;
      The investigators will conduct a prospective observational study of morbidly obese patients&#xD;
      undergoing RYGB, in which the investigators will measure the intestinal microbiome before and&#xD;
      after surgery along with insulin resistance and metabolic syndrome. Baseline measurements&#xD;
      will be done before the pre-operative run-in with the very low calorie Optifast regimen (800&#xD;
      kcal/d) given before the laparoscopic RYGB (1 week/100 lbs body weight) to reduce the liver&#xD;
      size for surgical access. Preoperatively, Optifast likely leads to changes in IM (never&#xD;
      assessed) in addition to weight loss and improvement in MetS parameters. Aim: To track the&#xD;
      changes in IM structure and function (metagenome) of morbidly obese patients undergoing&#xD;
      laparoscopic RYGB through 3 stages - a) before vs. after pre-op Optifast weight reduction&#xD;
      treatment 24; and post-op RYGB at b) 1 month; and at c) 6 months. The investigators will&#xD;
      correlate the specific changes in IM through these stages, to improvement in IR and other&#xD;
      features of the MetS. At the same time points the investigators will also measure the OM,&#xD;
      salivary flow rate and SP, as well as oral inflammatory load.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 2015</start_date>
  <completion_date type="Anticipated">July 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HOMA-IR</measure>
    <time_frame>Change from Baseline HOMA-IR at 6 months post bariatric surgery</time_frame>
    <description>HOMA-IR which represents insulin resistance and is calculated based on (glucose [mmol/L] x insulin [mU/L] / 22.5).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stool Sample: 16S sequencing</measure>
    <time_frame>4 time points; pre-Optifast (baseline), post-Optifast (at the time of surgery), 1 and 6 months post surgery</time_frame>
    <description>Stool sample analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool Sample: qPCR</measure>
    <time_frame>4 time points; pre-Optifast (baseline), post-Optifast (at the time of surgery), 1 and 6 months post surgery</time_frame>
    <description>Stool sample analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool Sample: Short Chain fatty acid</measure>
    <time_frame>4 time points; pre-Optifast (baseline), post-Optifast (at the time of surgery), 1 and 6 months post surgery</time_frame>
    <description>Stool sample analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool Sample: Metagenome.</measure>
    <time_frame>4 time points; pre-Optifast (baseline), post-Optifast (at the time of surgery), 1 and 6 months post surgery</time_frame>
    <description>Stool sample analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Appetite assessment</measure>
    <time_frame>4 time points; pre-Optifast (baseline), post-Optifast (at the time of surgery), 1 and 6 months post surgery</time_frame>
    <description>Appetite questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anthropometry:Height</measure>
    <time_frame>4 time points; pre-Optifast (baseline), post-Optifast (at the time of surgery), 1 and 6 months post surgery</time_frame>
    <description>Anthropometric height</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anthropometry: weight</measure>
    <time_frame>4 time points; pre-Optifast (baseline), post-Optifast (at the time of surgery), 1 and 6 months post surgery</time_frame>
    <description>Anthropometric weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anthropometry: Waist circumference</measure>
    <time_frame>4 time points; pre-Optifast (baseline), post-Optifast (at the time of surgery), 1 and 6 months post surgery</time_frame>
    <description>Anthropometric measurements (measured in cm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anthropometry: Hip-circumference</measure>
    <time_frame>4 time points; pre-Optifast (baseline), post-Optifast (at the time of surgery), 1 and 6 months post surgery</time_frame>
    <description>Anthropometric measurements (measured in cm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaires: Food record</measure>
    <time_frame>4 time points; pre-Optifast (baseline), post-Optifast (at the time of surgery), 1 and 6 months post surgery</time_frame>
    <description>General questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaires: Activity Log</measure>
    <time_frame>4 time points; pre-Optifast (baseline), post-Optifast (at the time of surgery), 1 and 6 months post surgery</time_frame>
    <description>General questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaires: Environmental questionnaire</measure>
    <time_frame>4 time points; pre-Optifast (baseline), post-Optifast (at the time of surgery), 1 and 6 months post surgery</time_frame>
    <description>General questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaires: Dental questionnaire,</measure>
    <time_frame>4 time points; pre-Optifast (baseline), post-Optifast (at the time of surgery), 1 and 6 months post surgery</time_frame>
    <description>General questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral microbiome: Saliva</measure>
    <time_frame>4 time points; pre-Optifast (baseline), post-Optifast (at the time of surgery), 1 and 6 months post surgery</time_frame>
    <description>Oral sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral microbiome: Mouth rinse</measure>
    <time_frame>4 time points; pre-Optifast (baseline), post-Optifast (at the time of surgery), 1 and 6 months post surgery</time_frame>
    <description>Oral sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral microbiome: Oral Plaque</measure>
    <time_frame>4 time points; pre-Optifast (baseline), post-Optifast (at the time of surgery), 1 and 6 months post surgery</time_frame>
    <description>Oral sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral microbiome: Tongue plaque</measure>
    <time_frame>4 time points; pre-Optifast (baseline), post-Optifast (at the time of surgery), 1 and 6 months post surgery</time_frame>
    <description>Oral sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C peptide</measure>
    <time_frame>4 time points; pre-Optifast (baseline), post-Optifast (at the time of surgery), 1 and 6 months post surgery</time_frame>
    <description>Blood work measurements (measured in pmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>4 time points; pre-Optifast (baseline), post-Optifast (at the time of surgery), 1 and 6 months post surgery</time_frame>
    <description>Blood work measurements (measured in %)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose</measure>
    <time_frame>4 time points; pre-Optifast (baseline), post-Optifast (at the time of surgery), 1 and 6 months post surgery</time_frame>
    <description>Blood work measurement (measured mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Insulin</measure>
    <time_frame>4 time points; pre-Optifast (baseline), post-Optifast (at the time of surgery), 1 and 6 months post surgery</time_frame>
    <description>Blood work measurement (measured in pmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma endotoxin</measure>
    <time_frame>4 time points; pre-Optifast (baseline), post-Optifast (at the time of surgery), 1 and 6 months post surgery</time_frame>
    <description>Blood work measurement of lipopolysaccharide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut Hormone</measure>
    <time_frame>4 time points; pre-Optifast (baseline), post-Optifast (at the time of surgery), 1 and 6 months post surgery</time_frame>
    <description>Blood work measurement</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Roux-en-Y gastric bypass surgery (RYGB)</arm_group_label>
    <description>Morbidly obese patients undergoing gastric bypass surgery</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Stool samples, blood samples, dental and tongue plaque, saliva&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Obese patients undergoing RYGB surgery.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Morbidly obese patients (BMI &gt; 40 kg/m2 or BMI &gt;35-40 kg/m2 with other severe weight&#xD;
             loss responsive comorbidities, undergoing laparoscopic RYGB surgery).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  regular intake of non-steroidal anti-inflammatory drugs; prebiotics, probiotics or&#xD;
             antibiotics or any experimental drug in the 3 months prior to study entry; type 1&#xD;
             diabetes, chronic gastrointestinal diseases, previous gastrointestinal surgery&#xD;
             modifying the anatomy, smoking; pregnancy or breastfeeding; patients not tolerating&#xD;
             Optifast; bariatric surgery other than RYGB patients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johane P Allard, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Health Network, Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Lewis MC, Phillips ML, Slavotinek JP, Kow L, Thompson CH, Toouli J. Change in liver size and fat content after treatment with Optifast very low calorie diet. Obes Surg. 2006 Jun;16(6):697-701.</citation>
    <PMID>16756727</PMID>
  </reference>
  <reference>
    <citation>Chaffee BW, Weston SJ. Association between chronic periodontal disease and obesity: a systematic review and meta-analysis. J Periodontol. 2010 Dec;81(12):1708-24. doi: 10.1902/jop.2010.100321. Epub 2010 Aug 19. Review.</citation>
    <PMID>20722533</PMID>
  </reference>
  <reference>
    <citation>Madsbad S, Dirksen C, Holst JJ. Mechanisms of changes in glucose metabolism and bodyweight after bariatric surgery. Lancet Diabetes Endocrinol. 2014 Feb;2(2):152-64. doi: 10.1016/S2213-8587(13)70218-3. Epub 2014 Feb 3.</citation>
    <PMID>24622719</PMID>
  </reference>
  <reference>
    <citation>Graessler J, Qin Y, Zhong H, Zhang J, Licinio J, Wong ML, Xu A, Chavakis T, Bornstein AB, Ehrhart-Bornstein M, Lamounier-Zepter V, Lohmann T, Wolf T, Bornstein SR. Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters. Pharmacogenomics J. 2013 Dec;13(6):514-22. doi: 10.1038/tpj.2012.43. Epub 2012 Oct 2.</citation>
    <PMID>23032991</PMID>
  </reference>
  <reference>
    <citation>Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, Liang S, Zhang W, Guan Y, Shen D, Peng Y, Zhang D, Jie Z, Wu W, Qin Y, Xue W, Li J, Han L, Lu D, Wu P, Dai Y, Sun X, Li Z, Tang A, Zhong S, Li X, Chen W, Xu R, Wang M, Feng Q, Gong M, Yu J, Zhang Y, Zhang M, Hansen T, Sanchez G, Raes J, Falony G, Okuda S, Almeida M, LeChatelier E, Renault P, Pons N, Batto JM, Zhang Z, Chen H, Yang R, Zheng W, Li S, Yang H, Wang J, Ehrlich SD, Nielsen R, Pedersen O, Kristiansen K, Wang J. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012 Oct 4;490(7418):55-60. doi: 10.1038/nature11450. Epub 2012 Sep 26.</citation>
    <PMID>23023125</PMID>
  </reference>
  <reference>
    <citation>Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, Almeida M, Arumugam M, Batto JM, Kennedy S, Leonard P, Li J, Burgdorf K, Grarup N, Jørgensen T, Brandslund I, Nielsen HB, Juncker AS, Bertalan M, Levenez F, Pons N, Rasmussen S, Sunagawa S, Tap J, Tims S, Zoetendal EG, Brunak S, Clément K, Doré J, Kleerebezem M, Kristiansen K, Renault P, Sicheritz-Ponten T, de Vos WM, Zucker JD, Raes J, Hansen T; MetaHIT consortium, Bork P, Wang J, Ehrlich SD, Pedersen O. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013 Aug 29;500(7464):541-6. doi: 10.1038/nature12506.</citation>
    <PMID>23985870</PMID>
  </reference>
  <reference>
    <citation>Arimatsu K, Yamada H, Miyazawa H, Minagawa T, Nakajima M, Ryder MI, Gotoh K, Motooka D, Nakamura S, Iida T, Yamazaki K. Oral pathobiont induces systemic inflammation and metabolic changes associated with alteration of gut microbiota. Sci Rep. 2014 May 6;4:4828. doi: 10.1038/srep04828.</citation>
    <PMID>24797416</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 13, 2017</study_first_submitted>
  <study_first_submitted_qc>October 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2018</study_first_posted>
  <last_update_submitted>July 6, 2021</last_update_submitted>
  <last_update_submitted_qc>July 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Health Network, Toronto</investigator_affiliation>
    <investigator_full_name>Johane Allard</investigator_full_name>
    <investigator_title>Professor, Gastroenterologist</investigator_title>
  </responsible_party>
  <keyword>Morbidly obese</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>Metabolic syndrome</keyword>
  <keyword>Intestinal microbiome</keyword>
  <keyword>Gastric bypass</keyword>
  <keyword>Oral microbiome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

